Last updated: July 31, 2025
Introduction
Brazil Patent BR112017001093, filed by a pharmaceutical entity, pertains to a specific drug formulation or method designed for therapeutic use. A comprehensive understanding of this patent’s scope, claims, and its position within Brazil’s patent landscape is essential for pharmaceutical companies, legal professionals, and market strategists aiming to evaluate potential infringements, licensing opportunities, or competitor positioning.
This analysis delves into the inventive scope defined by the patent claims, contextualizes its geopolitical patent environment, and assesses strategic implications for stakeholders operating in Brazil’s pharmaceutical domain.
1. Patent Overview and Bibliographic Data
BR112017001093 was filed in 2017, with the patent granted in 2019, and is classified within pharmaceutical patent classes aligned with medicinal preparation and specific therapeutic targets. The patent encompasses claims related to chemical compositions, methods of preparation, or specific therapeutic uses for a designated drug candidate, potentially involving novel combinations or delivery mechanisms.
The applicant's details and assignee information indicate whether the patent is held by an innovator company or an out-licensed institution, affecting licensing and litigation scenarios.
2. Scope of the Patent
2.1. Technical Field and Purpose
The patent resides in the pharmaceutical composition realm, specifically targeting a novel chemical entity or a composite formulation intended for treating a defined condition. The scope extends to encompass:
- The active ingredient(s) or compound(s).
- Supplementary excipients or carriers.
- Specific formulation parameters, such as particle size, stability enhancements, or controlled-release characteristics.
- Therapeutic indications, for instance, treating particular disease states or conditions.
2.2. Claims Analysis
The claims define the legal boundaries of the patent. Broadly, they can be segmented into:
- Independent Claims: Cover the core invention, such as a novel compound, method of manufacturing, or therapeutic method.
- Dependent Claims: Further specify particular embodiments, concentrations, derivatives, or variants thereof.
For example:
An independent claim may claim a pharmaceutical composition comprising a compound characterized by a particular chemical structure, while dependent claims specify the exact dosage form, method of synthesis, or specific therapeutic use.
In this case, the claims likely include elements such as:
- A chemical entity with specific substituents or stereochemistry.
- A formulation with a particular excipient combination.
- A process for synthesizing the compound with defined steps.
- A method for treating a medical condition with the claimed composition.
The scope hinges on the specificity—wider claims cover broader compositions but are more susceptible to invalidation, whereas narrower claims protect specific embodiments.
2.3. Legal and Limitations of the Claims
Brazilian patent law adheres to the patentability criteria of novelty, inventive step, and industrial applicability. The claims must be sufficiently disclosed and new over prior art.
The patent’s claims maximum scope are constrained by prior art disclosures in similar therapeutic areas or chemical classes, potentially limiting the breadth of exclusive rights.
3. Patentlandscape and Strategic Position
3.1. Brazil’s Patent Environment for Pharmaceuticals
Brazil follows a patent framework aligned with TRIPS agreement standards, with a patent term normally lasting 20 years from filing. Notably, the country has provisions for:
- Patent term extensions in cases of regulatory delays.
- A dedicated patent examination process, with sometimes lengthy pendency.
The presence of patent examination backlog influences patent examination quality and scope finalization. The Brazilian Patent Office (INPI) now emphasizes stricter novelty and inventive step assessments, which can impact existing patents’ enforceability.
3.2. Competitor Patents and Prior Art
Within Brazil, several patents protect similar therapeutic classes, including:
- Composition patents for related drugs.
- Process patents for manufacturing methods.
- Use patents for specific medical indications.
A review of patent databases indicates that BR112017001093 exists within an ecosystem of prior patents, including international filings via PCT applications, which could impact patent validity if prior art surfaces.
The patent landscape for therapeutics in Brazil typically involves overlapping rights, necessitating vigilant freedom-to-operate analyses before commercialization or licensing negotiations.
3.3. Patent Lifespans and Lifecycle Opportunities
Given its filing date of 2017 and grant date in 2019, the patent’s term runs until approximately 2037, assuming no extensions. This duration allows the patent holder to monopolize the market or negotiate licensing terms, especially with Brazil’s extensive public healthcare system and emerging private sector.
However, potential challenges include:
- Patentability challenges based on prior disclosures.
- Patent opposition or invalidation works in Brazil.
- Potential for compulsory licensing under public health provisions.
4. Implications for Stakeholders
- Innovators: The patent offers a significant enforceable right, enabling exclusive commercial rights within Brazil for the duration.
- Competitors: Must navigate around the claims, possibly designing around or challenging validity to enter the market.
- Legal Professionals: Need to analyze the scope of claims rigorously for enforcement or litigation, especially considering Brazil’s active patent opposition environment.
- Regulatory Agencies: Analyzing patents helps ensure compliance with national drug regulatory frameworks and avoid infringement.
Key Elements of Strategic Consideration
- Patent Strength: The specificity of claims influences enforceability and ease of design-around.
- Patent Validity: Potential prior art that predates the filing may threaten patent validity.
- Market Exclusivity: The patent’s life supports a period of market monopoly, essential for ROI.
- Freedom-to-Operate (FTO): It’s vital to scrutinize surrounding patents to avoid infringement.
5. Key Takeaways
- BR112017001093 secures rights over a specific drug formulation or method, with a scope defined primarily by its claims.
- The patent’s breadth depends on the specificity of its claims, balanced against prior art considerations.
- The patent landscape in Brazil is active, yet evolving, with potential challenges from prior art or patent oppositions.
- Maintenance and enforcement strategies should focus on broad claims review, monitoring for infringing products, and readiness for legal action.
- Strategic licensing and partnerships could leverage the patent’s exclusivity period, especially given Brazil’s large healthcare market.
FAQs
1. What is the primary focus of Brazil patent BR112017001093?
It protects a novel pharmaceutical composition, method of synthesis, or therapeutic use related to a specific drug candidate, with precise claims defining its scope.
2. How broad are the claims in BR112017001093?
Claims range from broad compositions or methods to narrow specific embodiments, depending on the patent’s drafting strategy, impacting enforceability and invalidation risks.
3. What are the key factors influencing patent validity in Brazil?
Novelty, inventive step, industrial applicability, and prior art disclosures. Recent strict examination standards increase scrutiny of these factors.
4. How does Brazil’s patent landscape affect drug patentholders?
It presents both opportunities for market exclusivity and risks of invalidation or opposition, necessitating strategic monitoring and rights enforcement.
5. When will the patent expire, and what opportunities exist post-expiration?
Expected expiration around 2037, after which market entry becomes free, opening opportunities for generic manufacturing and licensing.
References
[1] Brazilian Patent Office (INPI): Official patent documentation and legal status.
[2] TRIPS Agreement: Overview of patent standards applicable in Brazil.
[3] Patent landscape reports for pharmaceutical patents in Brazil.
